What Does Low Estrogen Feel Like in a Man?

A man on testosterone therapy comes back six weeks in and says his knees hurt, his libido has gone flat, his eyes are dry and he feels emotionally blank. His testosterone is excellent. The obvious reading is that something else is wrong. The correct reading, most of the time, is that his estradiol has been driven into the floor by a drug he was given to prevent a side effect he never had. It is one of the most common avoidable problems in men's hormone care, and it persists because its symptoms are almost indistinguishable from the condition it gets mistaken for.

Why men need estradiol at all

Men make estradiol continuously, from their own testosterone, via an enzyme called aromatase that sits in fat tissue, bone, brain and blood vessel walls. This is not a leak in the system. It is a designed step, and a substantial fraction of what testosterone does in a man's body it does after being converted.

Estradiol in men governs bone density, joint cartilage maintenance, libido, erectile function, mood, lipid metabolism and aspects of cognition (Khosla et al., J Clin Endocrinol Metab 1998). The cleanest demonstration came from an experiment that separated the two hormones deliberately: healthy men had their natural axis suppressed, then received testosterone at varying doses with or without an aromatase inhibitor blocking conversion. Much of what gets attributed to "low T" turned out to track estradiol instead — particularly the body fat increase and the drop in libido (Finkelstein et al., N Engl J Med 2013).

The practical translation is uncomfortable for anyone who has spent years trying to minimise estrogen: the relationship is a U-shape, not a slope. Too high causes problems, too low causes different problems, and the bottom of the U is not at the left-hand edge of the graph. The protective role of estradiol in men covers the upside.

The symptom cluster

• Joint pain — usually the first sign and usually the one dismissed. Knees, shoulders, hands, hips: stiffness and ache, worse in the morning, better with movement, almost always filed under "getting older."
• Crashed libido despite normal or high testosterone. This combination is the most diagnostically useful thing on the list.
• Erectile difficulty, since estradiol participates in nitric oxide signalling in vascular tissue.
• Flat or depressed mood — anhedonia and blunted range rather than classic sadness. Men describe feeling switched off.
• Insomnia and night sweats.
• Dry eyes and dry skin, an underrated tell because it rarely gets mentioned.
• Brain fog and slower processing.
• Bone density loss over time, entirely silent until a scan or a fracture.
• Hot flashes in some men, which surprises them.

Why it gets misread as low testosterone

Set that list against untreated hypogonadism and the overlap is nearly total: low libido, flat mood, fatigue, poor sleep, cognitive fog. That is the trap. A man reports symptoms that sound like undertreatment, the intuitive response is to blame estrogen and increase the aromatase inhibitor, and he gets worse while every number on his panel except one looks better.

Four features discriminate low estradiol from low testosterone:

• Joint pain is the standout. Low testosterone does not typically produce new, symmetrical, multi-joint aching. Low estradiol does.
• The mismatch itself. Poor libido alongside a genuinely good testosterone level points away from testosterone as the explanation.
• Dryness. Dry eyes and dry skin are not part of the low-testosterone picture.
• The timeline. Symptoms that started or worsened after an aromatase inhibitor was added, or after its dose increased, are telling you what changed.

If three of those four are present, the answer is usually not more aromatase inhibitor.

Common causes

• Aromatase inhibitor overuse on testosterone therapy — far and away the most common cause, and the only entirely iatrogenic one. When anastrozole is and is not appropriate is worth reading first.
• Very low body fat. Adipose tissue is where much of the aromatase lives; get lean enough and conversion capacity falls with it.
• Very high training volume without adequate recovery or fuelling.
• Severe caloric restriction, which suppresses the axis broadly.
• Genetically low aromatase activity, uncommon but real.
• Medications including letrozole and exemestane, prescribed for other indications.

How to test correctly

This is where men get a wrong answer from a real laboratory. Use the sensitive estradiol assay (LC-MS/MS), not the standard immunoassay. The standard test was designed for women and is unreliable below about 50 pg/mL — the entire range that matters in men. It is not slightly imprecise there; it can be wrong in either direction, so a man can be reassured by a number that was never measuring anything.

• LabCorp: test code 140244
• Quest Diagnostics: test code 30289

Optimal in men sits around 20-35 pg/mL. Below 15 is clearly low. And the number is only interpretable next to the testosterone it came from, drawn at a consistent point in the injection cycle — an estradiol read at peak testosterone means something different from one read at trough. Estradiol management on TRT covers the full clinical picture.

Fixing it, and what to expect

1. Reduce or stop the aromatase inhibitor. Single biggest lever, and usually sufficient on its own.
2. Reconsider the testosterone protocol. If total testosterone sits in the lower-middle range, there may not be enough substrate for adequate conversion. More frequent, smaller injections also produce steadier levels than large infrequent ones, which reduces the peaks that prompted the aromatase inhibitor in the first place.
3. Address very low body fat where relevant. Returning to roughly 12-15% often normalises conversion without any medication change.
4. Pull back excessive cardio temporarily if training volume is part of the picture.
5. Re-test sensitive estradiol at six weeks, not at two. Levels move faster than symptoms, and testing too early produces a confusing snapshot.
6. In genuinely resistant cases, very low-dose estradiol supplementation exists as an option, strictly under physician guidance.

The recovery timeline matters, because men who do not know it abandon the correction before it works. Estradiol itself normalises quickly once the inhibitor stops. Mood, libido and mental clarity follow within about two to three weeks. Joint pain is slower, improving over weeks rather than days, because cartilage and synovial tissue take time to respond. Bone is slowest of all, over months — which is the argument for catching this early rather than tolerating it. Expect, and do not panic about, some water retention as estradiol returns to normal; that sensation is what drove most men to the aromatase inhibitor in the first place, and it settles.

The prescribing habit that causes this

Aromatase inhibitors are prescribed alongside testosterone far more often than the evidence supports, frequently at the outset and before anyone has established that a given man aromatises excessively. The logic is prophylactic — block estrogen before it causes bloating or breast tenderness. The flaw is that most men on a well-run protocol never develop those symptoms, and the ones who do can usually be handled by adjusting the testosterone rather than adding a second drug.

The better sequence: start without an aromatase inhibitor, use a schedule that avoids large peaks, measure sensitive estradiol alongside testosterone at steady state, and treat a genuinely high estradiol that has symptoms behind it — not a number in isolation, and not pre-emptively. That is what a properly supervised protocol looks like from the start.

Bottom line

Low estradiol in men is real, recognisable and largely iatrogenic — caused by treatment rather than by the condition being treated. It produces joint pain, crashed libido despite good testosterone, flat mood, dryness and silent bone loss, and because that cluster mimics undertreatment it frequently prompts the exact wrong response. Sensitive estradiol testing, a target of roughly 20-35 pg/mL rather than "as low as possible," and a prescribing approach that does not reach for an aromatase inhibitor by default are what prevent it. When it happens, stopping the inhibitor resolves most of it within a few weeks — with joints and bone taking longer.

Educational content, not medical advice. Laboratory interpretation and any treatment decision are made by a licensed physician after individual evaluation. Individual results vary.